Recent comments from Robert F. Kennedy Jr. have sparked fresh discussions in the peptide and medical research communities. During an appearance on The Joe Rogan Experience, hosted by Joe Rogan, he mentioned that the U.S. government may reconsider the regulatory status of several peptides currently restricted by the FDA.

According to his remarks, approximately 14 peptides could potentially be removed from the FDA’s Category 2 list. If such a change occurs, compounding pharmacies may once again be allowed to prepare these substances under federal guidelines. For clinics and research organizations that focus on peptide-based therapies, this could represent a significant regulatory development.

Before exploring the peptides themselves, it is useful to understand what Category 2 actually represents.

Understanding FDA Category 2

The U.S. Food and Drug Administration (FDA) oversees which substances compounding pharmacies are permitted to use when preparing customized medications.

When a compound is placed in Category 2, it usually indicates that regulators have identified possible safety issues or believe that the available scientific evidence is insufficient. Because of these concerns, pharmacies are generally restricted from compounding medications that contain those substances.

Many researchers argue that this limitation has created challenges. When regulated pharmacies cannot supply certain peptides, researchers sometimes rely on research-grade sources that may not always meet pharmaceutical manufacturing standards.

Advocates of reclassification believe that moving certain peptides out of Category 2 could allow them to be produced again in licensed and controlled pharmacy settings.

14 Peptides Frequently Mentioned in Reclassification Discussions

Although the FDA has not released an official confirmed list, industry conversations often point to a group of peptides that may be under review. These compounds are widely studied in areas such as regenerative medicine, metabolism, neuroscience, and immune function.

Below are the peptides commonly mentioned in these discussions.

1. BPC-157

BPC-157 is a peptide derived from a protein found in gastric juices. It has gained attention in regenerative medicine because researchers are studying its potential role in tissue repair and inflammation control.

Animal studies suggest it may support healing in tendons, muscles, and parts of the digestive system, which is why it is frequently examined in sports injury research.

2. Thymosin Alpha-1

Thymosin Alpha-1 is known for its role in regulating the immune system. In some countries, it has been used to support immune responses in certain viral infections and immune-related conditions.

Scientists continue to investigate its potential for strengthening immune function during illness and recovery.

3. TB-500

TB-500 is a synthetic form of thymosin beta-4, a naturally occurring peptide involved in cell movement and tissue repair.

Researchers are interested in how it may help direct cells toward damaged areas in the body, which could support healing processes in muscles and other tissues.

4. GHK-Cu

GHK-Cu, often referred to as a copper peptide, naturally occurs in the human body. It plays an important role in tissue regeneration and collagen production.

Because of these properties, it is frequently studied in dermatology, skin regeneration, and cosmetic research.

5. AOD-9604

AOD-9604 is a fragment derived from human growth hormone. Unlike the full hormone, it primarily focuses on fat metabolism.

Researchers have explored its potential role in obesity research because it may influence fat breakdown without producing the broader hormonal effects associated with growth hormone.

6. CJC-1295

CJC-1295 is designed to stimulate the body’s natural production of growth hormone.

It is often studied alongside other peptides because of its possible effects on recovery, sleep quality, and muscle maintenance, particularly in anti-aging research.

7. Ipamorelin

Ipamorelin also encourages the body to release growth hormone. However, it is often described as more selective compared to other compounds.

This selectivity may allow it to increase growth hormone levels while having a limited effect on other hormones, which is why it is frequently explored in metabolic research.

8. Epitalon

Epitalon has become well known in longevity research. Some studies suggest it may affect telomeres, the protective ends of chromosomes that naturally shorten as people age.

Because of this connection, researchers study Epitalon for possible roles in aging and cellular repair processes.

9. KPV

KPV is a short peptide composed of three amino acids. It originates from a larger hormone known as alpha-MSH.

Scientific interest in KPV focuses mainly on its potential anti-inflammatory properties, especially in the digestive system. Some studies examine its possible relevance in inflammatory bowel conditions.

10. MOTS-C

MOTS-C stands out because it originates from the mitochondria, the energy-producing structures inside cells.

Early research suggests it may influence metabolism, energy balance, and insulin sensitivity, making it a topic of interest in metabolic disease studies.

11. Semax

Semax is a synthetic peptide that has been studied for its potential neuroprotective effects.

Research has explored whether it may support memory, concentration, and cognitive function. Some studies have also looked at its role in neurological recovery.

12. Selank

Selank is another peptide associated with brain function. Researchers are interested in its possible anti-anxiety and immune-modulating properties.

Unlike many traditional anxiety treatments, Selank may not produce strong sedative effects, which has drawn attention in neuroscience research.

13. Kisspeptin-10

Kisspeptin-10 plays a key role in the regulation of reproductive hormones.

It helps control the release of hormones that influence puberty and fertility. Scientists are exploring its potential use in fertility treatments and hormone regulation studies.

14. DSIP (Delta Sleep-Inducing Peptide)

DSIP, also known as Emideltide, is associated with sleep regulation and circadian rhythm control.

Although research is still limited, scientists continue to study its possible involvement in sleep patterns, stress responses, and overall sleep quality.

Why Potential Reclassification Matters

If these peptides are eventually removed from Category 2, compounding pharmacies in the United States may once again be able to prepare them under physician supervision.

This would allow these compounds to be produced in regulated pharmacy environments rather than relying solely on research-grade suppliers.

However, it is important to understand that removal from Category 2 does not mean FDA approval. Each peptide would still require further clinical evidence and regulatory evaluation before being widely used in medical practice.

For now, no final regulatory decision has been announced. The comments made by Robert F. Kennedy Jr. have simply brought renewed attention to the issue, and many in the research community are watching closely for possible policy updates in the coming months.